http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106279398-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-505 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 |
| filingDate | 2015-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106279398-B |
| titleOfInvention | A kind of Erythropoietin mimetic peptide and its preparation method and application |
| abstract | The present invention relates to a kind of Erythropoietin mimetic peptide and its dimer, the simulating peptide is sequence simulating peptide as shown in SEQ ID NO:1: SEQ ID NO:1GGLYAC 6 HMGPITX 1 VC 15 QPLRX 2 KC；Wherein, X 1 For 3- (1- naphthalene)-l-Alanine (Nal), X 2 For sarcosine (Sar), 6 and 15 cysteines (C) form intramolecular disulfide bond, N-terminal acetylation, and the dimer is that the simulating peptide is coupled two methylene benzene to be formed.The present invention also provides the simulating peptide and the preparation methods and its officinal salt of dimer.The present invention still further provides the pharmaceutical composition containing above-mentioned simulating peptide or dimer or its officinal salt.Erythropoietin mimetic peptide, dimer and its officinal salt of the invention can stimulate RBC acceptor garland rate, and significantly extend the half-life period of drug in vivo. |
| priorityDate | 2015-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 265.